Purpose: This study sought to describe patient characteristics and treatment patterns among patients with insomnia prescribed trazodone in the United States. Methods: This real-world, retrospective, descriptive cohort study used US commercial insurance claims from July 1, 2009, through June 30, 2019. The index date was the first prescription for trazodone between January 1, 2010, and December 31, 2018, with 6 months for the preindex period and ≥6 months for the postindex period. Findings: Among 5.8 million patients with insomnia, 17.7% were prescribed trazodone, and 357,380 adults (6.2%) and 7564 children (0.1%) met the study eligibility criteria. The mean (SD) age was 48.8 (15.8) years for adults and 14.8 (2.7) years for pediatrics. Most patients were female (229,280 adults [64.2%] and 4481 children [59.2%]). Insomnia due to mental disorder was the most common specific diagnosis. The most common (>25%) comorbid conditions were anxiety, depression, and hypertensive disease, and 1 of 10 had a history of substance abuse. Zolpidem was previously prescribed (73,342 adults [20.5%] and 233 children [3.1%]) and continued to be prescribed. Concomitant antidepressants were most common (216,893 adults [60.7%] and 5414 children [71.6%]), but benzodiazepines (132,740 adults [37.1%] and 1188 children [15.7%]), antiepileptics (115,064 adults [32.2%] and 2103 children [27.8%]), nonbenzodiazepines (90,946 adults [25.4%] and 542 children [7.2%]), and antipsychotics (40,490 adults [11.3%] and 2063 children [27.3%]) were also prescribed. Implications: This study provides current evidence that trazodone use is widespread among patients with insomnia and is often associated with other specific comorbidities, such as psychiatric conditions. A deeper knowledge of the real-world management of patients with insomnia may facilitate steps toward improving sleep quality, daytime functioning, and clinical outcomes for patients.

Real-World Characteristics and Treatment Patterns of Patients With Insomnia Prescribed Trazodone in the United States / Pochiero, I.; Gorini, M.; Comandini, A.; Calisti, F.; Loreto, G. D.; Cattaneo, A.; Knight, T.; Anastassopoulos, K. P.; Patel, R.; Baik, R.; Bruni, O.. - In: CLINICAL THERAPEUTICS. - ISSN 0149-2918. - 44:8(2022), pp. 1093-1105. [10.1016/j.clinthera.2022.07.004]

Real-World Characteristics and Treatment Patterns of Patients With Insomnia Prescribed Trazodone in the United States

Patel R.;Bruni O.
2022

Abstract

Purpose: This study sought to describe patient characteristics and treatment patterns among patients with insomnia prescribed trazodone in the United States. Methods: This real-world, retrospective, descriptive cohort study used US commercial insurance claims from July 1, 2009, through June 30, 2019. The index date was the first prescription for trazodone between January 1, 2010, and December 31, 2018, with 6 months for the preindex period and ≥6 months for the postindex period. Findings: Among 5.8 million patients with insomnia, 17.7% were prescribed trazodone, and 357,380 adults (6.2%) and 7564 children (0.1%) met the study eligibility criteria. The mean (SD) age was 48.8 (15.8) years for adults and 14.8 (2.7) years for pediatrics. Most patients were female (229,280 adults [64.2%] and 4481 children [59.2%]). Insomnia due to mental disorder was the most common specific diagnosis. The most common (>25%) comorbid conditions were anxiety, depression, and hypertensive disease, and 1 of 10 had a history of substance abuse. Zolpidem was previously prescribed (73,342 adults [20.5%] and 233 children [3.1%]) and continued to be prescribed. Concomitant antidepressants were most common (216,893 adults [60.7%] and 5414 children [71.6%]), but benzodiazepines (132,740 adults [37.1%] and 1188 children [15.7%]), antiepileptics (115,064 adults [32.2%] and 2103 children [27.8%]), nonbenzodiazepines (90,946 adults [25.4%] and 542 children [7.2%]), and antipsychotics (40,490 adults [11.3%] and 2063 children [27.3%]) were also prescribed. Implications: This study provides current evidence that trazodone use is widespread among patients with insomnia and is often associated with other specific comorbidities, such as psychiatric conditions. A deeper knowledge of the real-world management of patients with insomnia may facilitate steps toward improving sleep quality, daytime functioning, and clinical outcomes for patients.
2022
Claims database; Insomnia; Patient characteristics; Real-world; Trazodone; Treatment patterns
01 Pubblicazione su rivista::01a Articolo in rivista
Real-World Characteristics and Treatment Patterns of Patients With Insomnia Prescribed Trazodone in the United States / Pochiero, I.; Gorini, M.; Comandini, A.; Calisti, F.; Loreto, G. D.; Cattaneo, A.; Knight, T.; Anastassopoulos, K. P.; Patel, R.; Baik, R.; Bruni, O.. - In: CLINICAL THERAPEUTICS. - ISSN 0149-2918. - 44:8(2022), pp. 1093-1105. [10.1016/j.clinthera.2022.07.004]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1692918
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 2
social impact